Form 4: Abbott Laboratories Director Kevin Conroy Receives RSU Grant

Abbott Laboratories director Kevin T. Conroy was granted 2,286 restricted stock units under the company's 2026 Incentive Stock Program.

Summary

• Director Kevin T. Conroy acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
• The grant was issued under the Abbott Laboratories 2026 Incentive Stock Program.
• The RSUs are payable on a one-to-one basis in common shares upon separation from service, death, or a change in control.
• Following this transaction, the director's total beneficial ownership stands at 133,737 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on the company's financial outlook.

Positives

• Director alignment with long-term shareholder interests through equity-based compensation.
• The grant reflects standard corporate governance practices for director compensation.

Negatives

• None identified.

Risks

• Value of the equity grant is subject to future fluctuations in Abbott Laboratories' share price.

Future Outlook

The RSUs will vest and be paid out upon the director's separation from service, death, or a change in control of the company.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard industry practice in the healthcare and pharmaceutical sectors to ensure long-term alignment between leadership and shareholders.

Comparison to Industry Standards

• The use of RSU grants for directors is consistent with compensation structures at peer companies like Medtronic, Danaher, and Thermo Fisher Scientific.
• The vesting schedule tied to separation from service is a common retention and alignment mechanism for non-employee directors.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Insider Trading, Director Compensation, Restricted Stock Units